Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 11/2001

01-11-2001 | Review Article

Effects of Antibacterials on the Unborn Child

What is Known and How Should This Influence Prescribing

Authors: Ms Adrienne Einarson, Samar Shuhaiber, Gideon Koren

Published in: Pediatric Drugs | Issue 11/2001

Login to get access

Abstract

Antibacterials are among the most commonly prescribed drugs worldwide. In general, infections occur in pregnant women at much the same rate as in the general population. However, as a result of physiological changes brought about by pregnancy, some infections, such as those of the urinary tract, may have an increased incidence. It is important to remember that almost every drug crosses the placenta, ensuring that the unborn fetus is also exposed.
When prescribing an antibacterial agent to a pregnant woman, it is important that the mother is treated appropriately while at the same time protecting the unborn child. Certain factors need to be addressed, such as the possible teratogenic risk, changes in pharmacokinetics and the potential toxicity of the drug.
In this paper we have reviewed various classes of antibacterials which are commonly used during pregnancy, including penicillins, β-lactam inhibitors, cephalosporins, macrolides, aminoglycosides, tetracyclines, lincosamides, fluoroquinolones, sulfonamides, nitrofurans, and anti-tubercular agents. Some of these drugs have been on the market for many years, whereas others are relatively new and increasingly popular, despite the fact that the older drugs remain very effective. After reviewing the evidence-based information from epidemiological studies, it appears that most antibacterial agents can be used relatively safely during pregnancy.
Women who are pregnant should not be denied appropriate antibacterial therapy because of a lack of information. It is possible to treat the mother, while protecting the unborn child, by prescribing an agent that the causative bacteria is sensitive to, rather than a perceived ‘safer’ option that may not effectively treat the infection and which may also add to the growing problem of bacterial resistance.
Literature
1.
Chow AW, Jewesson PJ. Pharmacokinetics and safety of antimicrobial agents during pregnancy. Rev Infect Dis 1985; 7: 287–313PubMedCrossRef
2.
Philipson A. Pharmacokinetics of antibiotics in pregnancy and labour. Clin Pharmacokinet 1979; 4: 297–309PubMedCrossRef
3.
Koren G. Maternal-fetal toxicology: a clinicians guide. 2nd ed. New York: Marcel Dekker, 1994: 6–7
4.
Turner G, Collins E. Fetal effects of regular salicylate ingestion during pregnancy. Lancet 1975; II: 338–9CrossRef
5.
Hegde AU, Parekji S, Ali US, et al. Angiotensin converting enzyme inhibitor fetopathy. Indian Pediatr 1999; 36(1): 79–82PubMed
6.
7.
Hutter A, Parks J. The transmission of penicillin through the placenta: a preliminary report. Am J Obstet Gynecol 1945; 49: 663–5
8.
Heinonen OP, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977: 435
9.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1097
10.
Pedler SJ, Bint AJ. Comparative study of amoxicillin/clavulinic acid and cephalexin in the treatment of bacteruria during pregnancy. Antimicrob Agents Chemother 1985; 27: 508–10PubMedCrossRef
11.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1089–96
12.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore (MD): Williams and Wilkins, 1994: 135–151
13.
Berkovitch M, Segal-Socher I, Greenberg R, et al. First trimester exposure to cefuroxamine: a prospective cohort study. Br J Clin Pharmacol 2000; 50(2): 161–5PubMedCrossRef
14.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1145
15.
MacCullock D. Vancomycin in pregnancy. NZ Med J 1981; 93: 93–4
16.
Reyes MP, Ostrea Jr EM, Cabinian AE. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol 1989; 161(4): 977–81PubMed
17.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1135–41
18.
Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin Pharmacol Ther 1976; 19: 68–77PubMed
19.
McCormack WM, George H, Donner A. Hepatotoxicity of erythromycin estolate during pregnancy. Anti Microb Agents Chemother 1977; 12: 630–5CrossRef
20.
Einarson A, Philips E, Mawje F, et al. A prospective controlled study of clarithromycin in pregnancy. Am J Perinatol 1998; 15(9): 523–5PubMedCrossRef
21.
Bush MR, Rosa L. Azithromycin and erythromycin in the treatment of cervical chlamydia infection during pregnancy. Obstet and Gynecol 1994; 84(1): 61–3
22.
Desmonts G, Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. N Engl J Med 1974; 50: 1110–6CrossRef
23.
Carter AO, Frank JW. Congenital toxoplasmosis: epidemiological features and control. Can Med Assoc J 1986; 135: 618–23
24.
Desmonts G, Daffos F, Forrestier F, et al. Prenatal diagnosis of congenital toxoplasmosis. Lancet 1985; I: 500–4CrossRef
25.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1103–21
26.
Brummett RE. Animal models of aminoglycoside antibiotic ototoxicity. Rev Infect Dis 1983; 5 Suppl. 2: S294–303CrossRef
27.
Leroux Ml. Existe-t-l une surdite congenitale acquise due a la streptomycine? Ann Otolaryngol 1950; 67: 194–6PubMed
28.
Robinson GC, Cambon KG. Hearing loss in infants of mothers treated with streptomycin during pregnancy. N Engl J Med 1964; 281: 949–51CrossRef
29.
Conway N, Birt BD. Streptomycin in pregnancy: effect on the fetal ear. BMJ 1965; II: 260–3CrossRef
30.
Donald PR, Sellars SL. Streptomycin ototoxicity in the unborn child. S Afr Med J 1981; 60: 316–8PubMed
31.
Watson E, Stow R. Streptomycin therapy: effects on fetus. JAMA 1948; 137: 1599–600CrossRef
32.
Rubin A, Winston J, Rutledge M. Effects of streptomycin on the human fetus. Am J Dis Child 1951; 82: 14–6
33.
Kistner R. The use of streptomycin during pregnancy. Am J Obstet Gynecol 1950; 60: 422–6PubMed
34.
Heinonen OP, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977: 297–301
35.
Marynowski A, Sianozecka E. Comparison of the incidence of congenital malformations in neonates from healthy mothers and from patients treated because of tuberculosis. Ginekol Pol 1972; 43: 713–5PubMed
36.
37.
Freeman D, Matsen J, Arnold N. Amniotic fluid and maternal and cord serum levels of gentamicin after intra-amniotic instillation of in patients with premature rupture of the membranes. Am J Obstet Gynecol 1972; 113: 1138–41PubMed
38.
Jones HC. Intrauterine ototoxicity: a case report and review of the literature. J Natl Med Assoc 1973; 65: 201–3PubMed
39.
Nishimura H, Tanimura T. Clinical aspects of the teratogenicity of drugs. Amsterdam: Excerpta Medica, 1976: 131
40.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore (MD): Williams and Wilkins, 1994: 828–829
41.
Bourget P, Fernandez H, Delouis C, et al. Pharmacokinetics of tobramycin in pregnant women: safety and efficacy of a once-daily dose regimen. J Clin Pharm Ther 1991; 16: 167–76PubMedCrossRef
42.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1124–31
43.
Swallow JN. Discoloration of primary dentition after maternal ingestion of tetracycline in pregnancy. Lancet 1964; II: 611–2CrossRef
44.
45.
Heinonen O, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977: 297–313
46.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore (MD): Williams and Wilkins, 1994: 808–811
47.
48.
Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2000; 88(1): 27–33PubMedCrossRef
49.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1141–44
50.
Weinstein AJ, Gibbs RS, Gallagher M. Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol 1976; 124: 688–91PubMed
51.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore (MD): Williams and Wilkins, 1994: 186–187
52.
McCormak WM, Rosner B, Lee YH, et al. Effect on birthweight of erythromycin treatment of pregnant women. Obstet Gynecol 1987; 69: 202–7
53.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1065–68
54.
Quinolones and pregnancy: worrying animal findings, few clinical data. Prescrire Int 1999; 8(39): 29–31
55.
Danisovicova A, Brezina M, Belan S. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy: a multicenter survey. Chemotherapy 1994; 40: 209–14PubMedCrossRef
56.
Berkovitch M, Pastusak A, Gazarian M, et al. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994; 84(4): 535–8PubMed
57.
Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluroquinolones: a multicentre prospective controlled study. Antimicrob Agents Chemother 1998; 42(6): 1336–9PubMed
58.
Schaefer C, Amoura-Elefant E, Vial T, et al. Pregnancy outcome after prenatal quinolone exposure: evaluation of a case registry of the European network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 1996; 69(2): 83–9PubMedCrossRef
59.
Murray EDS. Nalidixic acid in pregnancy [letter]. BMJ 1977; I: 1332
60.
Heinonen OP, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977: 320
61.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1057–62
62.
Reid DWJ, Caillie G, Kaufman NR. Maternal and transplacental kinetics of trimethoprim and sulfamethoxazole,separately and in combination. Can Med Assoc J 1975; 1112: 67–72S
63.
Heinonen OP, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977: 458
64.
Kantor HI, Sutherland DA, Leonard JT, et al. Effect on bilirubin metabolism in the newborn of sulfisoxazole administration to the mother. Obstet Gynecol 1961; 17: 494–500PubMed
65.
Perkins RP. Fetal hydrops and stillbirth in a male glucose-6-phosphate dehydrogenase-deficient fetus possibly due to maternal ingestion of sulfisoxazole. Am J Obstet Gynecol 1971; 111: 379–81PubMed
66.
Diav-Citrin O, Park Y-H, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114: 23–8PubMedCrossRef
67.
Williams JD, Condie AP, Brumfitt W, et al. The treatment of bacteriuria in pregnant women with sulfamethoxazole and trimethoprim. Postgrad Med J 1969; 45 Suppl.: 71–6PubMed
68.
Ochoa AG. Trimethoprim and sulfamethoxazole in pregnancy [abstract]. JAMA 1971; 217: 1244CrossRef
69.
Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risks for birth defects. N Engl J Med 2000; 343(22): 1608–14PubMedCrossRef
70.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 995–8
71.
72.
Beard CM, Noller KL, O’Fallon WM, et al. Lack of evidence for cancer due to use of metronidazole. N Engl J Med 1979; 301: 519–22PubMedCrossRef
73.
Cantu JM, Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects Orig Artic Ser 1982; 18 (3 Pt A): 85–8PubMed
74.
Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993; 82(3): 348–52PubMed
75.
Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole. Br J Obstet Gynecol 1998; 105(3): 322–7CrossRef
76.
Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995; 172 (2 Pt 1): 525–9PubMedCrossRef
77.
Caro-Paton T, Carvajal A, Martin Amas LH, et al. Is metronidazole teratogenic: a meta-analysis. Br J Clin Pharmaco 1997; 44(2): 179–82CrossRef
78.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1069–1076
79.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore (MD): Williams and Wilkins, 1994: 876–78
80.
Hailey FJ, Fort H, Williams JC, et al. Foetal safety of nitrofurantoin macrocrystals therapy during pregnancy: a retrospective analysis. J Int Med Res 1983; 11: 364–9PubMed
81.
Lenke RR, Van Dorsten JP, Schifrin BS. Pylonephritis in pregnancy: a prospective randomised trial to prevent recurrent disease evaluating suppressive therapy with nitrofurantoin and close surveillance. Am J Obstet Gynecol 1983; 146: 953–7PubMed
82.
Ben DS, Einarson T, Nullman I, et al. The safety of nitrofurantoin during the first trimester: a meta-analysis. Clin Fundament Pharmacol 1995; 9(5): 503–7CrossRef
83.
Powell RD, deGowin RL, Alving AS. Nitrofurantoin-induced hemolysis. J Lab Clin Med 1963; 62: 1002–3
84.
Gordon SF. Asymptomatic bacteriuria of pregnancy. Clin Med 1972; 19: 22–4
85.
Furness ET, McDonald PJ, Beasley NV. Urinary antiseptics in asymptomatic bacteriuria of pregnancy. NZ Med J 1975; 81: 417–9
86.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore (MD): Williams and Wilkins, 1994: 561
87.
Heinonen OP, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977: 302
88.
89.
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of The British Thoracic Society. Thorax 1998 Jul; 53(7): 536–48CrossRef
90.
Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000 May 17; 283(19): 2537–45PubMedCrossRef
91.
Giosue S, Casarini M, Ameglio F, et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000; 11(1): 99–104PubMed
92.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1155–9
93.
McDonald AD. Maternal health in early pregnancy and congenital defect: final report on a prospective inquiry. Br J Prev Soc Med 1961; 15: 154–66
94.
Varpela E. On the effect exerted by first-line tuberculosis medicines on the fetus. Acta Tubercul Pneum Scand 1964; 35: 53–69
95.
Scheinhorn DJ, Angelillo VA. Antituberculosis therapy in pregnancy: risks to the fetus. West J Med 1977; 127: 195–8PubMed
96.
Heinonen OP, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977; 8: 299–313
97.
Snider Jr DE, Layde PM, Johnson MW. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980; 122: 65–79PubMed
98.
Wynn RM. The obstetric significance of factors affecting the metabolism of bilirubin, with particular reference to the role of Vitamin K. Obstet Gynecol Surv 1963; 18: 333–54PubMedCrossRef
99.
100.
Steen JSM, Stainton-Ellis DM. Rifampin in pregnancy. Lancet 1977; II: 604–5CrossRef
101.
Jentgens H. Antituberkulose chemotherapie und sshwanger-shaftsabburch. Prax Pneumol 1973; 27: 479–88PubMed
102.
Gupta KC, Ali MY. Failure of oral contraceptives with rifampicin [abstract]. Med J Zambia 1980; 15(1): 23
103.
Marcus JC. Non-teratogenicity of antituberculosis drugs. S Afr Med J 1967; 41(30): 758–9PubMed
104.
105.
Lewit T, Nebel L, Terracina S, et al. Ethambutamol in pregnancy: observations on embryogenesis. Chest 1974; 666: 25–6CrossRef
106.
Heinonen OP, Sloane D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977: 299
107.
Wall MA. Treatment of tuberculosis during pregnancy [letter]. Am Rev Respir Dis 1980; 122(6): 989PubMed
108.
Shepard CC. Experimental chemotherapy in leprosy then and now. Int J Lepr Other Mycobact Dis 1973; 41(3): 307–19PubMed
109.
Steiner RW, Omachi AS. A Barrter’s-like syndrome from capreomycin and a similar gentamicin tubulopathy. Am J Kidney Dis 1986; 7(3): 245–9PubMed
110.
Hardman JG, Limbird LE, Milinoff PB, et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1171
111.
Farb H, West DP, Pedvis-Leftick A. Clofazimine in pregnancy complicated by leprosy. Obstet Gynecol 1982; 59: 122–3PubMed
112.
Holdiness MR. Clofazimine in pregnancy. Early Human Devel 1989; 18: 297–8CrossRef
Metadata
Title
Effects of Antibacterials on the Unborn Child
What is Known and How Should This Influence Prescribing
Authors
Ms Adrienne Einarson
Samar Shuhaiber
Gideon Koren
Publication date
01-11-2001
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 11/2001
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/00128072-200103110-00003